Neurocrine Biosciences (NBIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$155.64-1.71%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NBIX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 3,373.9 | 2,860.5 | 2,355.3 | 1,887.1 | 1,488.7 | 1,133.5 | 1,045.9 | 788.1 | 451.2 | 161.6 | 15.0 | 19.8 | 0.0 | 2.9 | 53.1 | 77.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 161.6 | 15.0 | 19.8 | 0.0 | 2.9 | 53.1 | 77.4 |
| Cost of Revenues | — | 52.1 | 34.0 | 39.7 | 23.2 | 14.3 | 10.1 | — | 4.9 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 1,351.6 | 1,156.2 | 1,007.2 | 887.6 | 752.7 | 583.3 | 433.3 | 354.1 | 248.9 | 169.9 | — | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — | — | — | — | 160.5 | 121.8 | 94.3 | 81.5 | 46.4 | 39.2 | 37.2 | 31.0 |
| Operating Income | 794.8 | 619.1 | 570.5 | 250.9 | 249.0 | 102.5 | 163.0 | 72.3 | 36.8 | (131.4) | (147.4) | (94.2) | (64.4) | (49.7) | 1.4 | 33.9 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 4.6 | 7.1 | 25.8 | 32.8 | 32.0 | 30.5 | 19.5 | — | — | — | — | — | — |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | 2.8 | 1.9 | 0.6 | 0.4 | 0.5 | — |
| Other Non-Operating Income / Expenses | 145.4 | 86.3 | (84.5) | 81.2 | (35.1) | (1.1) | (56.3) | (25.8) | (15.0) | (11.2) | 6.3 | 5.3 | 3.9 | 3.6 | 3.6 | 3.6 |
| EBT, Incl. Unusual Items | 940.2 | 705.4 | 486.0 | 332.1 | 213.9 | 101.4 | 106.7 | 46.5 | 21.8 | — | — | — | — | — | — | — |
| Income Tax Expense | 234.7 | 226.8 | 144.7 | 82.4 | 59.4 | 11.8 | (300.6) | 9.5 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Net Income | 705.5 | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 | 407.3 | 37.0 | 21.1 | (142.5) | (141.1) | (88.9) | (60.5) | (46.1) | 5.0 | 37.6 |
| Per Share | ||||||||||||||||
| Basic EPS | 6.99 | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 | 4.38 | 0.40 | 0.23 | (1.62) | (1.63) | (1.05) | (0.81) | (0.69) | 0.08 | 0.68 |
| Diluted EPS | 6.77 | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | (1.62) | (1.63) | (1.05) | (0.81) | (0.69) | 0.08 | 0.67 |
| Revenue per Share | 32.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 101.0 | 99.5 | 100.4 | 97.7 | 95.8 | 94.6 | 93.1 | 91.6 | 90.2 | 88.1 | 86.7 | 84.5 | 74.6 | 67.0 | 65.6 | 55.2 |
| Diluted Weighted Avg Shares | 104.2 | 102.5 | 103.7 | 101.0 | 98.9 | 97.9 | 97.8 | 95.7 | 95.4 | 88.1 | 86.7 | 84.5 | 74.6 | 67.0 | 66.9 | 56.3 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | 40.8 | (129.0) | (145.9) | (93.2) | (63.6) | (49.0) | 2.1 | 34.6 |
| EBIT | 794.8 | 619.1 | 570.5 | 250.9 | 249.0 | 102.5 | 163.0 | 72.3 | 36.8 | (131.4) | (147.4) | (94.2) | (64.4) | (49.7) | 1.4 | 33.9 |
| Effective Tax Rate | 25.0% | — | — | 24.8% | 27.8% | 11.6% | -281.7% | 20.4% | 3.2% | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.